Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intercept Pharmaceuticals and Les Laboratoires Servier have signed an ex-US and Japan agreement to develop and discover agonists to treat type 2 diabetes and other metabolic indications.
Subscribe to our email newsletter
The tie up is focused on leveraging drug discovery platform of Intercept that is based on its proprietary bile acid analog chemistry and expertise targeting TGR5 and other bile receptors.
As per the terms of the agreement, Servier is responsible to pay a sum of around $163m in upfront payment, research support and milestone payments.
Further, the companies are expected to work together and implement their discover effort.
However, Servier alone will be responsible for all costs associated with the global development, regulatory approval and commercialization of any compound selected as a lead candidate by the parties.
Servier R&D head Emmanuel Canet said TGR5 is a target of great interest with its effects on GLP-1 that complement those of other classes of marketed diabetes drugs.